24446866|t|Long-term Abeta exposure augments mCa2+-independent mROS-mediated depletion of cardiolipin for the shift of a lethal transient mitochondrial permeability transition to its permanent mode in NARP cybrids: a protective targeting of melatonin.
24446866|a|Mitochondrial dysfunction is a hallmark of amyloid beta-peptide (Abeta)-induced neurodegeneration of Alzheimer's disease (AD). This study investigated whether mtDNA T8993G mutation-induced complex V inhibition, clinically associated with neurological muscle weakness, ataxia, and retinitis pigmentosa (NARP), is a potential risk factor for AD and the pathological link for long-term exposure of Abeta-induced mitochondrial toxicity and apoptosis in NARP cybrids. Using noninvasive fluorescence probe-coupled laser scanning imaging microscopy and NARP cybrids harboring 98% mutant genes along with its parental 143B osteosarcoma cells, we demonstrated that Abeta-augmented mitochondrial Ca(2+) (mCa(2+))-independent mitochondrial reactive oxygen species (mROS) formation for a cardiolipin (CL, a major mitochondrial protective phospholipid)-dependent lethal modulation of the mitochondrial permeability transition (MPT). Abeta augmented not only the amount but also the propagation rate of mROS-induced mROS formation to significantly depolarize mitochondrial membrane potential ( Psi(m)) and reduce mCa(2+) stress. Abeta-augmented mROS oxidized and depleted CL, thereby enhances mitochondrial fission and movement retardation, which promoted the NARP-augmented lethal transient-MPT (t-MPT) to switch to its irreversible mode of permanent-MPT (p-MPT). Interestingly, melatonin, a multiple mitochondrial protector, markedly reduced Abeta-augmented mROS formation and therefore significantly reduced mROS-mediated depolarization of  Psi(m), fission of mitochondria and retardation of mitochondrial movement to stabilize CL and hence the MPT. In the presence of melatonin, Abeta-promoted p-MPT was reversed to a protective t-MPT, which preserved  Psi(m) and lowered elevated mCa(2+) to sublethal levels for an enhanced mCa(2+)-dependent O(2) consumption. Thus, melatonin may potentially rescue AD patients associated with NARP symptoms.
24446866	10	15	Abeta	Gene	351
24446866	52	56	mROS	Chemical	-
24446866	127	140	mitochondrial	Disease	MESH:D028361
24446866	190	194	NARP	CellLine	
24446866	230	239	melatonin	Chemical	MESH:D008550
24446866	241	266	Mitochondrial dysfunction	Disease	MESH:D028361
24446866	306	311	Abeta	Gene	351
24446866	321	338	neurodegeneration	Disease	MESH:D019636
24446866	342	361	Alzheimer's disease	Disease	MESH:D000544
24446866	363	365	AD	Disease	MESH:D000544
24446866	406	412	T8993G	DNAMutation	tmVar:g|SUB|T|8993|G;HGVS:g.8993T>G;VariantGroup:0;CorrespondingGene:351;CorrespondingSpecies:9606
24446866	479	507	neurological muscle weakness	Disease	MESH:D018908
24446866	509	515	ataxia	Disease	MESH:D001259
24446866	521	541	retinitis pigmentosa	Disease	MESH:D012174
24446866	543	547	NARP	Disease	MESH:C537396
24446866	581	583	AD	Disease	MESH:D000544
24446866	636	641	Abeta	Gene	351
24446866	650	672	mitochondrial toxicity	Disease	MESH:D028361
24446866	690	694	NARP	Disease	MESH:C537396
24446866	787	791	NARP	Disease	MESH:C537396
24446866	851	868	143B osteosarcoma	CellLine	CVCL:2270
24446866	897	902	Abeta	Gene	351
24446866	913	926	mitochondrial	Disease	MESH:D028361
24446866	927	933	Ca(2+)	Chemical	-
24446866	935	942	mCa(2+)	Chemical	-
24446866	956	969	mitochondrial	Disease	MESH:D028361
24446866	970	993	reactive oxygen species	Chemical	MESH:D017382
24446866	995	999	mROS	Chemical	-
24446866	1017	1028	cardiolipin	Chemical	MESH:D002308
24446866	1042	1055	mitochondrial	Disease	MESH:D028361
24446866	1067	1079	phospholipid	Chemical	MESH:D010743
24446866	1116	1129	mitochondrial	Disease	MESH:D028361
24446866	1161	1166	Abeta	Gene	351
24446866	1230	1234	mROS	Chemical	-
24446866	1243	1247	mROS	Chemical	-
24446866	1286	1299	mitochondrial	Disease	MESH:D028361
24446866	1340	1347	mCa(2+)	Chemical	-
24446866	1356	1361	Abeta	Gene	351
24446866	1372	1376	mROS	Chemical	-
24446866	1420	1433	mitochondrial	Disease	MESH:D028361
24446866	1446	1466	movement retardation	Disease	MESH:C536300
24446866	1487	1491	NARP	Disease	MESH:C537396
24446866	1524	1529	t-MPT	Chemical	-
24446866	1607	1616	melatonin	Chemical	MESH:D008550
24446866	1629	1642	mitochondrial	Disease	MESH:D028361
24446866	1671	1676	Abeta	Gene	351
24446866	1687	1691	mROS	Chemical	-
24446866	1738	1742	mROS	Chemical	-
24446866	1822	1835	mitochondrial	Disease	MESH:D028361
24446866	1899	1908	melatonin	Chemical	MESH:D008550
24446866	1910	1915	Abeta	Gene	351
24446866	1960	1965	t-MPT	Chemical	-
24446866	2012	2019	mCa(2+)	Chemical	-
24446866	2056	2063	mCa(2+)	Chemical	-
24446866	2074	2078	O(2)	Chemical	-
24446866	2098	2107	melatonin	Chemical	MESH:D008550
24446866	2131	2133	AD	Disease	MESH:D000544
24446866	2134	2142	patients	Species	9606
24446866	2159	2172	NARP symptoms	Disease	MESH:C537396
24446866	Association	HGVS:g.8993T>G;CorrespondingGene:351	MESH:D018908
24446866	Positive_Correlation	HGVS:g.8993T>G;CorrespondingGene:351	MESH:D000544
24446866	Association	HGVS:g.8993T>G;CorrespondingGene:351	MESH:D012174
24446866	Association	MESH:D017382	351
24446866	Association	HGVS:g.8993T>G;CorrespondingGene:351	MESH:D001259
24446866	Association	HGVS:g.8993T>G;CorrespondingGene:351	MESH:C537396
24446866	Association	MESH:D010743	MESH:D028361
24446866	Negative_Correlation	MESH:D008550	351
24446866	Association	MESH:D017382	MESH:D028361
24446866	Association	MESH:D002308	351
24446866	Association	MESH:D028361	351
24446866	Negative_Correlation	MESH:D008550	MESH:D028361
24446866	Positive_Correlation	MESH:C536300	351
24446866	Association	MESH:D000544	351
24446866	Association	MESH:D002308	MESH:D028361
24446866	Association	MESH:D018908	351
24446866	Association	MESH:D000544	351
24446866	Association	MESH:D012174	351
24446866	Association	MESH:D001259	351
24446866	Association	MESH:C537396	351

